Brokerages Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Target Price at $43.80

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMGet Free Report) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $49.73.

Several equities analysts have weighed in on TNDM shares. Robert W. Baird lifted their price objective on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Leerink Partnrs raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. Barclays boosted their target price on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Stifel Nicolaus boosted their target price on shares of Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Piper Sandler restated an “overweight” rating and set a $50.00 price objective (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd.

Read Our Latest Report on Tandem Diabetes Care

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNDM. Commonwealth Equity Services LLC boosted its position in Tandem Diabetes Care by 10.1% in the third quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after buying an additional 908 shares in the last quarter. Raymond James & Associates boosted its position in shares of Tandem Diabetes Care by 1.9% during the third quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after purchasing an additional 737 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Tandem Diabetes Care by 18.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,506 shares of the medical device company’s stock worth $281,000 after purchasing an additional 2,103 shares in the last quarter. M&T Bank Corp bought a new position in shares of Tandem Diabetes Care during the third quarter worth $472,000. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth $2,230,000.

Tandem Diabetes Care Price Performance

NASDAQ TNDM opened at $49.68 on Tuesday. Tandem Diabetes Care has a 12 month low of $13.82 and a 12 month high of $52.51. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. The firm has a market capitalization of $3.21 billion, a PE ratio of -22.89 and a beta of 1.10. The company’s 50 day simple moving average is $36.78 and its 200 day simple moving average is $28.66.

Tandem Diabetes Care (NASDAQ:TNDMGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical device company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.17. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The firm had revenue of $191.67 million for the quarter, compared to analyst estimates of $173.06 million. As a group, equities research analysts forecast that Tandem Diabetes Care will post -1.7 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

(Get Free Report

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Featured Articles

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.